Although gene and molecular therapies targeting the primary defect of Dystrophin gene remain the most promising approach for DMD treatment, therapeutic strategies targeting the complex secondary mechanisms responsible for DMD pathogenesis are also being developed in parallel22. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.